Posted by Michael Wonder on 13 Feb 2017
NICE approves Incyte’s leukaemia drug for routine NHS use
13 February 2017 - NICE published draft guidance recommending ponatinib (Iclusig) for routine use on the NHS, to treat some patients with chronic myeloid leukaemia and acute lymphoblastic leukaemia.
Ponatinib is currently available to patients in the Cancer Drugs Fund. It had not been previously appraised by NICE. A positive recommendation by NICE, once final, means that ponatinib can come off the CDF and be routinely available to patients on the NHS.
The independent appraisal committee concluded that ponatinib offered effective treatment and benefits over other treatments, such as bosutinib, meaning it could be considered a clinically and cost effective use of NHS resources.
